<DOC>
	<DOCNO>NCT00604656</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety efficacy insulin aspart produce current process compare insulin aspart produce NN2000 process subject type 2 diabetes .</brief_summary>
	<brief_title>Comparison Insulin Aspart Produced NN2000 Process Current Process Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Subjects type 1 diabetes Duration diabetes least 12 month Treatment insulin aspart least 3 month trial start Body Mass Index ( BMI ) 35.0 kg/m2 HbA1c 12.0 % Total insulin dosage 1.4 IU/kg/day Recurrent major hypoglycaemia may interfere trial participation ( judged investigator ) Known hypoglycaemia unawareness judge investigator Known hypersensitivity allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>